Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine combined with low-intensity chemotherapy for children with refractory or relapsed acute myeloid leukemia
ChiCTR1800015872Phase 2Not yet recruiting
- Sponsor
- Children's Hospital of Soochow University
- Start
- Jun 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of decitabine, idarubicin, cytarabine, granulocyte colony-stimulating factor and homoharringtonine in acute myeloid leukemia (AML) (2 arms), sponsored by Children's Hospital of Soochow University. Primary endpoints: Bone marrow remission status, Hematologic remission and 4 more. Planned start Jun 2018; status: not yet recruiting.
02
Drugs
decitabineidarubicincytarabinegranulocyte colony-stimulating factorhomoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1800015872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015872.